Headset Tablet contains a combination of Sumatriptan 85 mg and Naproxen 500 mg, formulated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan, a selective serotonin receptor agonist (5-HT1B/1D), acts by constricting intracranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides, thereby alleviating migraine symptoms such as headache, nausea, and photophobia. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), provides additional analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis. The combination enhances therapeutic efficacy, addressing both vascular and inflammatory components of migraine pathophysiology. Headset Tablet is indicated for patients who require rapid and sustained relief from moderate to severe migraine attacks. It should be administered as early as possible after migraine onset, with dosing tailored to individual response and tolerability. Contraindications include hypersensitivity to either component, cardiovascular disease, uncontrolled hypertension, and history of ischemic stroke. Caution is advised in patients with hepatic or renal impairment. Common adverse effects may include dizziness, nausea, somnolence, and gastrointestinal discomfort. Patients should consult healthcare professionals before use to ensure appropriate management and to avoid potential drug interactions.